FT Pharma looks for early stage investors


May 23, 2013

Pharmaceutical company with enormous potential seeks early stage investors

A UK headquartered pharmaceutical development company which is building a profitable business deploying its marketing, product development and regulatory expertise to improve the efficacy, safety and patient compliance of existing drugs and devices in the fields of human gender health and chronic pain.

Product improvements will provide patent protection and create opportunities to optimise market penetration by competing with unenhanced, but trusted and effective, generic products.

Revenues will be generated in the first 12 months from product sales and the Company will achieve substantial value inflection points and licensing income within 12 months from its development pipeline.


For more information, please visit Dealmarket.com

Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn